Transitioning to regulatory harmonisation for medicines: a comparison between Africa and Europe
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Medicines regulation harmonization differs significantly between Europe and Africa. While Europe
Area Of Science
- Regulatory science
- Health policy
- Comparative analysis
Background
- Medicines regulation harmonization has progressed differently across global regions.
- Europe initiated harmonization over 50 years ago, while Africa's efforts are more recent and regionally focused.
- Understanding these divergent paths is crucial for future global health initiatives.
Purpose Of The Study
- To compare the regulatory development of medicines in Europe and Africa.
- To examine key factors influencing harmonization, including stakeholder influence, philosophy, funding, and systems.
- To identify common goals and critical differences in regulatory approaches.
Main Methods
- Comparative analysis of regulatory frameworks and historical developments in Europe and Africa.
- Examination of influencing factors such as legislation, economics, disease patterns, and industrial policy.
- Review of the roles of key institutions like the European Medicines Agency and the proposed African Medicines Agency.
Main Results
- Europe's success was driven by common binding legislation and the formation of the European Union.
- Africa's regulatory strengthening has been spurred by disease outbreaks and regional initiatives.
- Common goals include health protection and work-sharing, but differences in economics and disease patterns are significant.
- The European Medicines Agency's establishment was pivotal; an African Medicines Agency is still developing.
Conclusions
- National support is vital for supranational regulatory bodies in both regions.
- Africa shows recent regulatory advancements, while Europe continues to refine its system.
- Continued harmonization efforts are essential to address future global health challenges.
- Divergent historical contexts and drivers necessitate tailored approaches to regulatory harmonization.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...